June 10, 2024 – Ruvidar™, in combination with Bacillus Calmette-Guérin (BCG), significantly enhances the cancer cell-killing efficacy compared to BCG or Ruvidar™ alone, even without light activation.
Theralase® Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar™
Toronto, Ontario – September 29, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Compounds (“PDCs”), their associated drug formulations and the light systems that activate them. These PDCs are intended to safely and effectively destroy various cancers, bacteria and viruses, when light or radiation activated. Supported by current Good Manufacturing Practice (“cGMP”) analysis conducted by an independent manufacturing and testing laboratory, Theralase® announced that it has successfully demonstrated an 8 year, real-time, shelf life of its lead PDC, RuvidarTM. Dr. Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase® stated, “Theralase®’s ability to demonstrate such an extended shelf life of its lead PDC, RuvidarTM is extremely encouraging, as it supports our ongoing clinical development plans. This independent analysis confirms the ability of RuvidarTM to be an extremely stable small molecule that has the … Read More
Theralase® Successfully Destroys Lung Cancer
June 6, 2024 – Rutherrin®, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer (“NSCLC”).
Theralase® Technology Effective in Virus Inactivation
June 4, 2024 – Theralase’s lead compound, Ruvidar, has been proven effective in the inactivation of various viruses. The research was completed at the laboratory of Kevin Coombs, Ph.D., University of Manitoba in conjunction with National Microbiology Laboratory and Theralase® Technologies Inc.
Theralase® Release’s 1Q2024 Financial Statements
May 30, 2024 – Theralase releases the Company’s unaudited interim consolidated 1Q2024 Financial Statements
Theralase® Expands Clinical Team
May 2, 2024 – Theralase expands its clinical team with the hiring of two Clinical Research Associates.
Theralase® Granted Canadian Cancer Vaccine Patent
April 5th, 2024, Theralase® granted Canadian patent for a new cancer vaccine titled, “Vaccine Containing Cancer Cells Inactivated by Photodynamic Treatment with Metal-Based Coordination Complexes and Immunotherapy Method Using Same”.
Theralase® Release’s 4Q2023 Interim Financial Statements
March 27, 2024 – Theralase released the Company’s audited annual consolidated 2023 financial statements (“Financial Statements”).
Theralase® to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
V.TLT | March 26th, 2024 Toronto, Ontario – March 26th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that it is hosting Advisory Board meetings to present the latest Study II interim clinical data to its Principal Investigators (“PIs”) at the Canadian Urological Association (“CUA”) Bladder Cancer Forum and the American Urology Association (“AUA”), respectively. Study II is a Phase II clinical study that provides a Study Procedure (Study Drug activated by a Study Device) for patients diagnosed with Bacillus Calmette Guerin (“BCG”)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”). An advisory board meeting is scheduled to take place on April 12, 2024, during the Bladder Cancer Forum 2024 located in … Read More
Dr. Michael Jewett Joins Theralase® to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
V.TLT | February 8th, 2024 Toronto, Ontario – February 8th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (“PDCs“) for the safe and effective destruction of various cancers, bacteria and viruses is pleased to announce that Dr. Michael Jewett has joined Theralase®, in the role of an independent consultant, to assist the Company in the completion of enrollment of patients in the Phase II Bacillus Calmette-Guérin (“BCG”)-Unresponsive Non Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”) clinical study (“Study II”). Under the terms of the consulting agreement, Dr. Jewett will be responsible for working with existing clinical study sites and helping to onboard new clinical study sites to allow Theralase® to complete enrollment and provide the primary study treatment to all 100 patients in Study II, preferably by December 31, … Read More